{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T20:02:08Z","timestamp":1776542528410,"version":"3.51.2"},"reference-count":72,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":1621,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32HL007093"],"award-info":[{"award-number":["T32HL007093"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1002\/rth2.12102","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T02:42:52Z","timestamp":1525228972000},"page":"429-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Managing thrombosis in cancer patients"],"prefix":"10.1016","volume":"2","author":[{"given":"Tzu\u2010Fei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-2309","authenticated-orcid":false,"given":"Ang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/rth2.12102_bb0010","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer\u2010associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"key":"10.1002\/rth2.12102_bb0015","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1002\/rth2.12102_bb0020","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12102_bb0025","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low\u2010molecular\u2010weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12102_bb0030","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2017-03-743211","article-title":"Cancer\u2010associated pathways and biomarkers of venous thrombosis","volume":"130","author":"Hisada","year":"2017","journal-title":"Blood"},{"key":"10.1002\/rth2.12102_bb0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(01)00619-2","article-title":"Cancer and the prothrombotic state","volume":"3","author":"Lip","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1002\/rth2.12102_bb0040","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1084\/jem.20082297","article-title":"Cancer cell\u2010derived microparticles bearing P\u2010selectin glycoprotein ligand 1 accelerate thrombus formation in vivo","volume":"206","author":"Thomas","year":"2009","journal-title":"J Exp Med"},{"key":"10.1002\/rth2.12102_bb0045","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1158\/1078-0432.CCR-09-0371","article-title":"Tumor\u2010derived tissue factor\u2010bearing microparticles are associated with venous thromboembolic events in malignancy","volume":"15","author":"Zwicker","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1002\/rth2.12102_bb0050","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1538-7836.2012.04754.x","article-title":"Microparticle\u2010associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients","volume":"10","author":"Thaler","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12102_bb0055","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2013-04-460139","article-title":"Tumor\u2010derived tissue factor\u2010positive microparticles and venous thrombosis in cancer patients","volume":"122","author":"Geddings","year":"2013","journal-title":"Blood"},{"key":"10.1002\/rth2.12102_bb0060","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","article-title":"High plasma levels of soluble P\u2010selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"112","author":"Ay","year":"2008","journal-title":"Blood"},{"key":"10.1002\/rth2.12102_bb0065","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1160\/TH07-10-0608","article-title":"Prophylactic P\u2010selectin inhibition with PSI\u2010421 promotes resolution of venous thrombosis without anticoagulation","volume":"99","author":"Meier","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12102_bb0070","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nm1565","article-title":"Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood","volume":"13","author":"Clark","year":"2007","journal-title":"Nat Med"},{"key":"10.1002\/rth2.12102_bb0075","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/rth2.12102_bb0080","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy\u2010associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1002\/rth2.12102_bb0085","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"key":"10.1002\/rth2.12102_bb0090","first-page":"203","article-title":"Development and external validation of a risk assessment model for cancerassociated venous thromboembolism","volume":"1","author":"Pabinger","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1002\/rth2.12102_bb0095","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCULATIONAHA.111.051920","article-title":"Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer\u2010associated venous thromboembolism","volume":"126","author":"Louzada","year":"2012","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/rth2.12102_bb0100","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0049-3848(16)30106-2","article-title":"Predictors of recurrent venous thromboembolism and bleeding on anticoagulation","volume":"140","author":"Menapace","year":"2016","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12102_bb0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.thromres.2018.01.009","article-title":"Predicting the risk of recurrent venous thromboembolism in patients with cancer: a prospective cohort study","volume":"163","author":"van Es","year":"2018","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12102_bb0110","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood-2014-01-549733","article-title":"Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population\u2010based cohort study","volume":"123","author":"Chee","year":"2014","journal-title":"Blood"},{"key":"10.1002\/rth2.12102_bb0115","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2016.67.4564","article-title":"Tissue factor as a predictor of recurrent venous thromboembolism in malignancy: biomarker analyses of the CATCH Trial","volume":"35","author":"Khorana","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1002\/rth2.12102_bb0120","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/SLA.0000000000002074","article-title":"Perioperative pharmacological thromboprophylaxis in patients with cancer: a systematic review and meta\u2010analysis","volume":"265","author":"Guo","year":"2017","journal-title":"Ann Surg"},{"key":"10.1002\/rth2.12102_bb0125","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1245\/s10434-016-5127-1","article-title":"Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta\u2010analysis","volume":"23","author":"Fagarasanu","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1002\/rth2.12102_bb0130","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","article-title":"Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence\u2010based clinical practice guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"key":"10.1002\/rth2.12102_bb0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11239-015-1313-4","article-title":"Guidance for the prevention and treatment of cancer\u2010associated venous thromboembolism","volume":"41","author":"Khorana","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1002\/rth2.12102_bb0140","first-page":"CD008500","article-title":"Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"12","author":"Di Nisio","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1002\/rth2.12102_bb0145","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood.V130.Suppl_1.626.626","article-title":"An individual participant data meta\u2010analysis of 13 randomized trials to evaluate the impact of prophylactic use of heparin in oncological patients","volume":"130","author":"Sch\u00fcnemann","year":"2017","journal-title":"Blood"},{"key":"10.1002\/rth2.12102_bb0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.thromres.2017.01.009","article-title":"Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial","volume":"151","author":"Khorana","year":"2017","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12102_bb0155","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low\u2010molecular\u2010weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1002\/rth2.12102_bb0160","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180\u2010day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1002\/rth2.12102_bb0165","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long\u2010term low\u2010molecular\u2010weight heparin versus usual care in proximal\u2010vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am J Med"},{"key":"10.1002\/rth2.12102_bb0170","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"10.1002\/rth2.12102_bb0175","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1002\/rth2.12102_bb0180","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1200\/JOP.2015.004473","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"11","author":"Lyman","year":"2015","journal-title":"J Oncol Pract"},{"key":"10.1002\/rth2.12102_bb0185","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2015.0133","article-title":"Cancer\u2010associated venous thromboembolic disease, version 1.2015","volume":"13","author":"Streiff","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1002\/rth2.12102_bb0190","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1378\/chest.14-0402","article-title":"Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta\u2010analysis","volume":"147","author":"Vedovati","year":"2015","journal-title":"Chest"},{"key":"10.1002\/rth2.12102_bb0195","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.thromres.2014.09.039","article-title":"Efficacy and safety of anticoagulant therapy for the treatment of acute cancer\u2010associated thrombosis: a systematic review and meta\u2010analysis","volume":"134","author":"Carrier","year":"2014","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12102_bb0200","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.thromres.2015.07.011","article-title":"Treatment of venous thromboembolism in patients with cancer: a network meta\u2010analysis comparing efficacy and safety of anticoagulants","volume":"136","author":"Posch","year":"2015","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12102_bb0205","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.amjmed.2015.12.025","article-title":"Efficacy and safety of rivaroxaban in patients with venous thromboembolism and active malignancy: a single\u2010center registry","volume":"129","author":"Bott\u2010Kitslaar","year":"2016","journal-title":"Am J Med"},{"key":"10.1002\/rth2.12102_bb0210","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11239-016-1429-1","article-title":"Safe and effective use of rivaroxaban for treatment of cancer\u2010associated venous thromboembolic disease: a prospective cohort study","volume":"43","author":"Mantha","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1002\/rth2.12102_bb0215","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.thromres.2017.02.003","article-title":"Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease","volume":"152","author":"Theberge","year":"2017","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12102_bb0220","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/1076029616677800","article-title":"Oral rivaroxaban for the treatment of symptomatic venous thromboembolism in 400 patients with active cancer","volume":"23","author":"Pignataro","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1002\/rth2.12102_bb0225","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.thromres.2017.04.003","article-title":"A prospective study of rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2)","volume":"162","author":"Davies","year":"2018","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12102_bb0230","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer\u2010associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12102_bb0235","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1160\/TH16-12-0946","article-title":"Clinical impact of major bleeding in patients with venous thrombo\u2010embolism treated with factor Xa inhibitors or vitamin K antagonists","volume":"117","author":"Bleker","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12102_bb0240","first-page":"625","article-title":"Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select\u2010D Pilot Trial","volume":"130","author":"Young","year":"2017","journal-title":"Blood"},{"key":"10.1002\/rth2.12102_bb0245","article-title":"Direct oral anticoagulant (DOAC) versus low\u2010molecular\u2010weight heparin (LMWH) for treatmetn of cancer associatd thrombosis (CAT): a systemic review and meta\u2010analysis","author":"Li","year":"2018","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12102_bb0250","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Cuurrent practice patterons and patient persistence with anticoagulant treatments for cancer\u2010associated thrombosis","volume":"1","author":"Khorana","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1002\/rth2.12102_bb0255","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12\u00a0months: the DALTECAN Study","volume":"13","author":"Francis","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12102_bb0260","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","article-title":"Tinzaparin in cancer associated thrombosis beyond 6\u00a0months: TiCAT study","volume":"157","author":"Jara\u2010Palomares","year":"2017","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12102_bb0265","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0002-9343(01)00840-3","article-title":"Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy","volume":"111","author":"Luk","year":"2001","journal-title":"Am J Med"},{"key":"10.1002\/rth2.12102_bb0270","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1538-7836.2009.03326.x","article-title":"Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients","volume":"7","author":"Carrier","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12102_bb0275","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2014.04.028","article-title":"Dose escalation of low molecular weight heparin in patients with recurrent cancer\u2010associated thrombosis","volume":"134","author":"Ihaddadene","year":"2014","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12102_bb0280","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/jth.12955","article-title":"Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short\u2010term prognosis","volume":"13","author":"Schulman","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12102_bb0285","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/1078155210380293","article-title":"Incidence and risk factors of clinically significant chemotherapy\u2010induced thrombocytopenia in patients with solid tumors","volume":"17","author":"Hitron","year":"2011","journal-title":"J Oncol Pharm Pract"},{"key":"10.1002\/rth2.12102_bb0290","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/MBC.0000000000000539","article-title":"\u2018Sailing in troubled waters\u2019: a review of the use of anticoagulation in adult cancer patients with thrombocytopenia","volume":"27","author":"Ibrahim","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1002\/rth2.12102_bb0295","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/jth.12338","article-title":"Management of challenging cases of patients with cancer\u2010associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH","volume":"11","author":"Carrier","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"10.1002\/rth2.12102_bb0300","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/S0049-3848(16)30112-8","article-title":"Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE): patterns of use and outcomes","volume":"140","author":"Brunson","year":"2016","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12102_bb0305","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1182\/bloodadvances.2017006130","article-title":"Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation","volume":"1","author":"Li","year":"2017","journal-title":"Blood Adv"},{"key":"10.1002\/rth2.12102_bb0310","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2015-02-626788","article-title":"Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study","volume":"126","author":"Donato","year":"2015","journal-title":"Blood"},{"key":"10.1002\/rth2.12102_bb0315","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/jth.13387","article-title":"A meta\u2010analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation","volume":"14","author":"Zwicker","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12102_bb0320","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood-2017-02-767285","article-title":"Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin","volume":"129","author":"Mantia","year":"2017","journal-title":"Blood"},{"key":"10.1002\/rth2.12102_bb0325","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.thromres.2015.11.027","article-title":"Recurrent venous thromboembolism in glioblastoma","volume":"137","author":"Edwin","year":"2016","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12102_bb0330","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/j.1538-7836.2012.04817.x","article-title":"Epidemiology and prevention of catheter\u2010related thrombosis in patients with cancer","volume":"10","author":"Lee","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12102_bb0335","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3747\/co.22.2392","article-title":"Clinical challenges in patients with cancer\u2010associated thrombosis: Canadian expert consensus recommendations","volume":"22","author":"Carrier","year":"2015","journal-title":"Curr Oncol"},{"key":"10.1002\/rth2.12102_bb0340","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/j.1538-7836.2007.02613.x","article-title":"A pilot study of central venous catheter survival in cancer patients using low\u2010molecular\u2010weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study)","volume":"5","author":"Kovacs","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12102_bb0345","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jth.12071","article-title":"International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer","volume":"11","author":"Debourdeau","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1002\/rth2.12102_bb0350","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.thromres.2010.03.016","article-title":"Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta\u2010analysis","volume":"125","author":"Dentali","year":"2010","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12102_bb0355","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2010.34.0984","article-title":"Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients","volume":"29","author":"den Exter","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1002\/rth2.12102_bb0360","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/j.1538-7836.2011.04259.x","article-title":"Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer","volume":"9","author":"Dentali","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12102_bb0365","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/jth.12883","article-title":"Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH","volume":"13","author":"Di Nisio","year":"2015","journal-title":"J Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frth2.12102","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922018969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922018969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/rth2.12102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:19:01Z","timestamp":1762863541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922018969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S2475037922018969"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12102","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing thrombosis in cancer patients","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}